Core Viewpoint - BioStem Technologies Inc. is set to present at the 25th Annual Needham Virtual Healthcare Conference, highlighting its focus on regenerative medicine and perinatal tissue allograft products [1][2]. Company Overview - BioStem Technologies is a publicly traded biomedical innovator specializing in the development, manufacturing, and commercialization of advanced allograft solutions derived from perinatal tissue [3]. - The company utilizes proprietary technologies such as BioRetain®, CryoTek®, and SteriTek® to optimize the preservation of natural tissue properties for clinical use [3]. - BioStem's allografts are utilized by clinicians across various specialties, indicating a broad application of its products [3]. Quality Assurance - The company's quality management system and standard operating procedures have been accredited by the American Association of Tissue Banks (AATB), ensuring compliance with current Good Tissue Practices (cGTP) and current Good Manufacturing Processes (cGMP) [4]. - BioStem's product portfolio includes well-known brands such as Neox®, Clarix®, VENDAJE®, and American Amnion™, reflecting its commitment to quality [4].

Core Viewpoint - BioStem Technologies, Inc. is progressing towards a Nasdaq uplisting by filing its audited consolidated financial statements for the fiscal years ended December 31, 2024, and 2025, marking a significant milestone for the company [1][2]. Financial Progress - The company has published its audited financial statements for 2024 and 2025, which is a crucial step in establishing robust financial reporting processes [2]. - The appointment of a new CFO, auditor, and audit committee chair further emphasizes the company's commitment to improving its financial governance [2]. Corporate Strategy - Listing on Nasdaq is a top priority for BioStem, as it would enhance visibility, improve stock liquidity, provide a more accurate market valuation, and attract top talent [2]. - The company is focused on advancing its corporate initiatives, including the development and commercialization of perinatal tissue allograft products [1][2]. Quality Assurance - BioStem's quality management system and standard operating procedures have been accredited by the American Association of Tissue Banks (AATB), ensuring compliance with current Good Tissue Practices (cGTP) and Good Manufacturing Processes (cGMP) [3]. - The company offers a portfolio of quality brands, including Neox, Clarix, VENDAJE, and American Amnion™ [3]. Company Overview - BioStem Technologies is a publicly traded biomedical innovator specializing in advanced allograft solutions derived from perinatal tissue, utilizing proprietary technologies like BioRetain, CryoTek, and SteriTek [2]. - The company is committed to advancing innovation in regenerative medicine with a growing portfolio of products and expanding clinical research initiatives [2].

Core Insights - BioStem Technologies, Inc. reported a significant decline in revenue for Q4 2025, with net revenue of $10.1 million, a 55% decrease compared to Q4 2024, primarily due to reimbursement uncertainty and competitive pressures [5][6] - The company completed the acquisition of BioTissue Holdings Inc. in January 2026, which is expected to enhance its product portfolio and commercial reach [9][10] - BioStem anticipates first quarter 2026 revenue to be between $5 million and $6 million, with expectations for growth in the hospital business in the second half of the year [12] Recent Financial and Business Highlights - CEO Jason Matuszewski emphasized the company's strengthened position and diversification following the BioTissue acquisition, which expands its market presence [3] - The gross profit margin for Q4 2025 was 97%, up from 84% in Q4 2024, attributed to a shift in product mix [5] - Operating expenses increased to $17.3 million in Q4 2025 from $10.7 million in Q4 2024, largely due to charges for potentially uncollectible accounts receivable [6] Financial Results Overview - For the full year 2025, net revenue was $47.5 million, down from $69.7 million in 2024, driven by lower wound care volume [8] - Gross profit for 2025 was $44.4 million, or 94% of net revenue, compared to $55.9 million or 80% in 2024 [10] - The company reported a GAAP net loss of $6.6 million for 2025, a significant decline from a net income of $31 million in 2024 [11] Cash Position and Future Outlook - As of December 31, 2025, cash equivalents totaled $29.5 million, which decreased to approximately $16 million post-BioTissue acquisition [7] - The company expects to drive sequential and year-over-year growth in the hospital business after integrating the BioTissue assets and expanding its salesforce [12]

Core Insights - BioStem Technologies has appointed Jodi Ungrodt to its Board of Directors as the Audit Committee Chair, effective March 18, 2026, bringing 29 years of accounting leadership in the life sciences sector [1][2][3] Company Overview - BioStem Technologies is a MedTech company focused on developing, manufacturing, and commercializing placental-derived products for advanced wound care [1][4] - The company is recognized for its proprietary allograft portfolio derived from donated birth tissue, utilizing advanced processing technologies to preserve the natural properties of the tissues [4][9] Leadership and Governance - Jodi Ungrodt's extensive experience includes serving as a senior partner at Ernst & Young, where she advised life sciences companies on various financial matters, including IPOs and regulatory compliance [2][5] - As Audit Committee Chair, Ungrodt will oversee financial reporting, internal controls, and risk management practices at BioStem [5] - Ungrodt replaces Brandon Poe, who transitioned to the role of chief financial officer in August 2025 after serving on the board for three years [8] Strategic Direction - The company aims to expand its business beyond chronic wound care and increase its visibility in public markets in 2026 [3] - BioStem is committed to advancing innovation in regenerative medicine, with ongoing research to enhance the understanding and application of placental-derived tissue products [4][9]

Core Viewpoint - BioStem Technologies, Inc. will release its fourth quarter and full year 2025 financial results on March 24, 2026, and will host a conference call and webcast at 4:30 PM ET [1]. Group 1: Company Overview - BioStem Technologies is a leading MedTech company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products for regenerative medicine [1][3]. - The company utilizes a proprietary BioRetain processing method, which is designed to maintain growth factors and preserve tissue structure [3]. - BioStem's quality management system has been accredited by the American Association of Tissue Banks and complies with current Good Tissue Practices and Good Manufacturing Processes [3]. Group 2: Upcoming Events - The upcoming conference call and webcast will feature an overview of the quarter presented by CEO Jason Matuszewski and CFO Brandon Poe [2]. - Registration for the event is available through a provided link [2]. Group 3: Contact Information - For further inquiries, BioStem can be contacted via their website, email, or social media platforms [5].

Core Insights - BioStem Technologies, Inc. will present at the 46th Annual TD Cowen Healthcare Conference in Boston, MA, highlighting its focus on perinatal tissue-derived products for advanced wound care [1]. Company Overview - BioStem Technologies is a leading innovator in the MedTech sector, specializing in the development, manufacturing, and commercialization of allografts for regenerative therapies derived from perinatal tissue [3]. - The company utilizes its proprietary BioRetain® processing method, which is designed to maintain growth factors and preserve tissue structure, leveraging the latest research in regenerative medicine [3]. - BioStem's quality management system and standard operating procedures are accredited by the American Association of Tissue Banks (AATB) and comply with current Good Tissue Practices (cGTP) and current Good Manufacturing Processes (cGMP) [3]. - The company's product portfolio includes brands such as VENDAJE®, VENDAJE AC®, American Amnion™, American Amnion AC™, and Neox® and Clarix® product lines [3].

Core Insights - BioStem Technologies, Inc. emphasizes the importance of the FDA's recent openness to Bayesian statistical methodologies in clinical trial design, which could enhance the efficiency and effectiveness of clinical studies in wound care [1][2][6] Group 1: FDA's Evolving Stance - FDA Commissioner Dr. Martin Makary described the agency's evolving stance on Bayesian approaches as a "leap forward" for clinical science, highlighting their potential to improve trial design and data integration [2] - The FDA's shift aligns with emerging regulatory guidance on Bayesian methods, indicating a more flexible approach to clinical trial methodologies [2] Group 2: BioStem's Clinical Research - BioStem's recent peer-reviewed randomized controlled trial demonstrated that BioRetain-processed allografts achieved superior outcomes in treating diabetic foot ulcers (DFUs), with the BR-AC arm being almost twice as likely to achieve lasting wound closure compared to standard care [3][4] - The trial utilized advanced statistical methods, including Bayesian regression, to quantify treatment effects and improve understanding of wound healing across diverse patient populations [3][4] Group 3: Benefits of Bayesian Methodologies - Bayesian methodologies are particularly beneficial in regenerative medicine and wound care, where datasets are often smaller and variability is high, allowing for more informed clinical decision-making [5] - The incorporation of prior knowledge with new data through Bayesian frameworks supports probabilistic interpretation, enhancing the relevance of clinical insights for healthcare stakeholders [5] Group 4: Commitment to Innovation - BioStem is dedicated to advancing evidence-based innovation in wound care through rigorous clinical research and real-world data analysis, supported by proprietary technologies like BioRetain and CryoTek [7] - The company aims to optimize the preservation of the natural structural and biological integrity of amniotic tissue, which is crucial for effective regenerative therapies [7][9]

Core Viewpoint - BioStem Technologies, Inc. has commented on the withdrawal of all seven Local Coverage Determinations (LCDs) by the Centers for Medicare & Medicaid Services (CMS) for skin substitute grafts and cellular products for treating diabetic foot ulcers and venous leg ulcers, effective January 1, 2026, indicating that this will not impact patient access to their technology [1][2]. Company Overview - BioStem Technologies is a MedTech company focused on developing, manufacturing, and commercializing placental-derived products for advanced wound care [1]. - The company utilizes its proprietary BioRetain processing method, which is designed to maintain growth factors and preserve tissue structure [2]. - BioStem's quality management system has been accredited by the American Association of Tissue Banks (AATB) and complies with current Good Tissue Practices (cGTP) and Good Manufacturing Processes (cGMP) [2]. Market and Innovation - The company emphasizes the importance of high-quality clinical evidence for long-term adoption and value creation, committing to an evidence-based strategy [2]. - BioStem plans to continue investing in expanding its clinical data foundation to demonstrate the differentiated performance of its proprietary technology compared to alternatives [2]. Product Portfolio - BioStem's product portfolio includes brands such as AmnioWrap2™, VENDAJE, and American Amnion™, all processed at their FDA registered and AATB accredited site in Pompano Beach, Florida [2].

Core Viewpoint - BioStem Technologies, Inc. has received a 12-month status quo designation for its products, ensuring continued reimbursement eligibility for diabetic foot ulcers (DFU) and venous leg ulcers (VLU) through 2026, while coverage for pressure ulcers remains unaffected by recent CMS updates [1][2][3][4]. Group 1: Reimbursement and Coverage - The Centers for Medicare & Medicaid Services (CMS) has categorized products into three groups: Covered, Non-Covered, and 12-Month Status Quo, allowing products in the Status Quo category to remain eligible for reimbursement as long as they meet the "reasonable and necessary" standard [2]. - The final Local Coverage Determinations (LCDs) specifically apply to DFU and VLU, not affecting payments for other wound types, thus maintaining consistent care for non-DFU/VLU patients [3]. - BioStem's largest reimbursement segment, related to pressure ulcers, remains unchanged, allowing continued use of its products without coverage interruption [3]. Group 2: Company Strategy and Future Plans - The CEO of BioStem expressed confidence that the status quo designation will ensure uninterrupted payment for its products in DFU and VLU applications throughout 2026, while also preserving access and revenue stability for the company's core pressure ulcer business [4]. - BioStem has submitted new clinical and scientific data to CMS, demonstrating the superiority of its products over standard care, and plans to engage in further discussions with CMS regarding its clinical trial findings [4]. - The company aims to transition its products from Status Quo to Covered status during the 2027 reconsideration cycle, emphasizing its commitment to generating clinical evidence and ensuring access to its placental allografts [4].

Core Points - BioStem Technologies Inc. will release its second quarter 2025 financial results on August 14, 2025, and will host a conference call and webcast at 4:30 PM ET [3][4] - The conference call will include a review of the financial results and updates on the Company's Form 10 filing and Nasdaq uplisting, led by CEO Jason Matuszewski and CFO Michael Fortunato [4] - BioStem Technologies focuses on the development, manufacture, and commercialization of placental-derived products for advanced wound care, utilizing its proprietary BioREtain® processing method [6][7] Company Overview - BioStem Technologies is recognized as a leading innovator in the MedTech sector, specializing in allografts for advanced wound care [6] - The Company’s quality management systems are accredited by the American Association of Tissue Banks (AATB) and comply with Good Tissue Practices (cGTP) and Good Manufacturing Processes (cGMP) [7] - BioStem's product portfolio includes brands such as AmnioWrap2™, VENDAJE®, and American Amnion™, all processed at its FDA registered and AATB accredited facility in Pompano Beach, Florida [7]